Company Description
Starton is a clinical-stage biotechnology company focused on improving standard-of-care therapies for people with cancer through application of our proprietary platform of delivery technology systems.
We use continuous delivery of FDA-approved, active ingredients in an attempt to develop and bring products to market in either new indications or with enhanced outcomes in existing indications.
In collaboration with our consulting company, McKinsey & Company, we evaluated over 80,000 potential applications to identify those applications where we believed our continuous delivery technology would bring the most benefit to patients.
Based on the results of that evaluation, we are focused initially on the treatment of hematologic malignancies (blood cancers).
Our algorithms also seek to identify drug candidates in areas of significant unmet medical needs that have not been able to achieve FDA approval due to tolerability concerns.
This process allows us to prioritize targeted opportunities.
| Country | United States |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Pedro Lichtinger Waisman |
Contact Details
Address: 215 College Road, Suite 300 Paramus, NJ 07652 United States | |
| Phone | (800) 449-5405 |
| Website | startontx.com |
Stock Details
| Ticker Symbol | STA |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 2049977 |
| Employer ID | 33-2448745 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Pedro Lichtinger Waisman | Chairman and Chief Executive Officer, Director |
| Eric Baum | Director |
| Moses Dodo | Director |
| Nitin Kaushal | Director |
| Roy F. Waldron | Director |
| Pedro Lichtinger Waisman | Chairman and Chief Executive Officer |
| James C. Oliver | Chief Medical Officer |
| Scott L. Kahn | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 11, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Mar 21, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Dec 31, 2024 | DRS | [Cover] Draft Registration Statement |